Open an account

Seres Therapeutics

MCRB · NASDAQ

$2.31−$0.11 (−4.55%)TodayMarket closed ·
Prev close $2.42

About MCRB

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Employees
66
Headquarters
Cambridge, Massachusetts
Listed
Jun 26, 2015
Sector
Health Care
Industry
Biotechnology
Website
serestherapeutics.com

MCRB key statistics

Market cap
22.96M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
73.31K
Volume
66.99K
Open price
$2.41
High today
$2.55
Low today
$2.31
52 Week high
$29.98
52 Week low
$2.39

Seres Therapeutics (MCRB) at a glance

As of Oct 20, 2026, Seres Therapeutics (MCRB) shares are priced at $2.31, giving the company a market cap of 22.96M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.31 and $2.55. The current price is 0.0% above the day's low and 9.4% below its high.

Volume so far is 66.99K shares, in line with the average of 73.31K shares a day.

Over the past year Seres Therapeutics has ranged from $2.39 to $29.98, and now sits 0% of the way up that range.

Seres Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.50 per share against an estimate of -$2.23.

The average analyst price target is $17.34, 650.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $17.34
Low
$12.12
Now
$2.31
High
$23.10

MCRB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 27.7% on average.

  1. Q3 FY24: reported -$7.60 per share against an estimate of -$5.01
  2. Q4 FY24: reported -$2.00 per share against an estimate of -$4.02
  3. Q1 FY25: reported -$2.96 per share against an estimate of -$0.5508
  4. Q2 FY25: reported -$2.27 per share against an estimate of -$2.54
  5. Q3 FY25: reported $0.94 per share against an estimate of $1.31
  6. Q4 FY25: reported -$1.78 per share against an estimate of -$2.15
  7. Q1 FY26: reported -$2.08 per share against an estimate of -$1.92
  8. Q2 FY26: reported -$1.50 per share against an estimate of -$2.23

MCRB news

  • Press releaseGlobe Newswire

    Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

  • Vandana Singh

    Seres Therapeutics Posts Early Data for Cancer Therapy Complication

  • Press releaseGlobe Newswire

    Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

  • Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis

  • Press releaseGlobe Newswire

    Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

  • Press releaseGlobe Newswire

    Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

  • Press releaseGlobe Newswire

    Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Similar companies

Companies in the same industry as Seres Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.